CytoHub is an AI-driven cardiac biology company building human-relevant platforms that improve how cardiac drugs, digital health solutions, and cell-based therapies are developed and scaled.

CytoHub combines proprietary AI, functional human mini-heart systems, and digital heart modeling to generate predictive cardiac data that traditional animal and 2D models cannot. The platform supports drug developers, digital health teams, and therapeutic innovators seeking earlier, more reliable insight into cardiac function, safety, and performance across discovery, development, and manufacturing.

With customers in market and growing commercial engagements, CytoHub helps developers reduce development risk, shorten timelines, and improve translational outcomes. We welcome conversations with investors and partners interested in advancing cardiac innovation through more predictive, human-relevant approaches.